Citius Pharmaceuticals
CTXR
76 hedge funds and large institutions have $43.2M invested in Citius Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 10 closing their positions.
676% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $135K
0% more funds holding
Funds holding: 76 → 76 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.19% less ownership
Funds ownership: 16.72% → 16.53% (-0.19%)
24% less capital inflows, than outflows
Capital inflows: $1.34M | Capital outflows: $1.75M
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$352K |
| 2 |
Goldman Sachs
New York
|
+$143K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$109K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$100K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$74.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$249K |
| 2 |
Barclays
London,
United Kingdom
|
-$186K |
| 3 |
HRT Financial
New York
|
-$139K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$138K |
| 5 |
AGM
Alpine Global Management
New York
|
-$129K |
CTXR Hedge Fund Activity: Q1 2022 in Review
76 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2022, worth a combined $43.2M — up 15% from $37.6M a quarter earlier.
Fund positioning in CTXR was balanced in Q1 2022: 10 funds opened new positions, 10 closed out, 19 added to existing stakes and 26 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $352K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $249K sold.
- 76 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $43.2M of Citius Pharmaceuticals stock for Q1 2022, up 15% quarter-over-quarter.
- 10 funds opened new Citius Pharmaceuticals positions in Q1 2022 and 10 closed out, a net change of 0 holders.
- The largest Citius Pharmaceuticals buyer in Q1 2022 was Geode Capital Management, an estimated $352K added.
- The largest Citius Pharmaceuticals seller in Q1 2022 was Two Sigma Investments, an estimated $249K sold.
Based on aggregated 13F filings for Q1 2022.